Clinical trial · Interventional
the Clinical Efficacy of Robotic and Laparoscopic Radical Total Gastrectomy in Locally Advanced Middle and Upper Gastric Cancer
A Prospective, Multicenter, Randomized, Controlled Study of the Clinical Efficacy of Robotic and Laparoscopic Radical Total Gastrectomy in Locally Advanced Middle and Upper Gastric Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the clinical efficacy (safety, feasibility and long-term efficacy) of robotic radical total gastrectomy and laparoscopic radical total gastrectomy in patients with locally advanced middle and upper gastric adenocarcinoma (CT2-4A, N-/+, M0) .
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Robotic Gastrectomy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Laparoscopic radical total gastrectomy with D2 lymphadenectomy | Procedure | — | UNRESOLVED |
| Robotic radical total gastrectomy with D2 lymphadenectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Robotic radical total gastrectomy with D2 lymphadenectomy
- description
- After exploration and randomization, patients received robotic radical total gastrectomy with D2 lymphadenectomy
- interventionNames
- Procedure: Robotic radical total gastrectomy with D2 lymphadenectomy
- type
- ACTIVE_COMPARATOR
- label
- Laparoscopic radical total gastrectomy with D2 lymphadenectomy
- description
- After exploration and randomization, patients received laparoscopic radical total gastrectomy with D2 lymphadenectomy
- interventionNames
- Procedure: Laparoscopic radical total gastrectomy with D2 lymphadenectomy
Primary outcomes (1)
- measure
- 3-year disease free survival rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * 1.Age between 18 and 75 years 2.The primary gastric lesion was histopathologically diagnosed as middle and upper gastric adenocarcinoma (papillary adenocarcinoma PAP, tubular adenocarcinoma TUB, mucinous adenocarcinoma MUC, signed-ring cell carcinoma SIG, poorly differentiated adenocarcinoma POR) by endoscopic biopsy. 3.Preoperative clinical stages were CT2-4A、 N-/+、and M0 (according to AJCC-8th TNM tumor staging) 4.Excepting to perform radical total gastrectomy and D2 lymph node dissection can achieve R0 resection. 5.American Society of Anesthesiology (ASA) score class I, II, or III 6.Written informed consent Exclusion Criteria: 1. Preoperative examination suggested disease staging cT1, N-/+, and M0 (according to AJCC-8th TNM tumor staging ) 2. Women during pregnancy or breast-feeding 3. Severe mental disorder 4. History of previous upper abdominal surgery (except laparoscopic cholecystectomy) 5. History of previous gastrectomy(except for ESD/EMR for gastric cancer ) 6. Enlarged or bulky regional lymph node over 3 cm by preoperative imaging 7. History of other malignant disease within the past five years 8. History of previous neoadjuvant chemotherapy or radiotherapy 9. History of unstable angina or myocardial infarction within past six months 10. History of cerebrovascular accident within past six months 11. History of continuous systematic administration of corticosteroids within one month 12. Requirement for simultaneous surgery for other disease(except laparoscopic cholecystectomy) 13. Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer 14. FEV1 (forced expiratory volume in one second)\<50% of predicted values
References
Publications (0)
Data not yet available